• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ANNX

ANNX

Annexon, Inc.

NASDAQHealthcareBiotechnologyUS

USD5.39

+0.13 (+2.47%)

Rating:C

Company Profile

CEO

Douglas E. Love

IPO Date

2020-07-24

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.25

Prev. Close

$5.26

Day Low

$5.20

Day High

$5.43

52W Low

$1.85

52W High

$7.18

Market Cap

$0.64B

Volume

2.89M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

30.4%

Avg Negative

12.1%

Avg Neutral

57.4%

News Feed

Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update

GlobeNewsWire·8/16/2021·↑ positive

Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

GlobeNewsWire·7/22/2021·↑ positive

Annexon to Present at the Raymond James Human Health Innovation Conference

GlobeNewsWire·6/16/2021·↑ positive

Moving Average Crossover Alert: Annexon (ANNX)

Zacks Investment Research·5/21/2021·↓ negative

Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference

GlobeNewsWire·5/5/2021·↑ positive

Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy

Benzinga·3/1/2021·↑ positive

Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy

GlobeNewsWire·3/1/2021·↑ positive

Annexon Welcomes William H. Carson, M.D.

GlobeNewsWire·2/8/2021·↓ negative

Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics

GlobeNewsWire·1/12/2021·↑ positive

Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference

GlobeNewsWire·1/5/2021·↑ positive